Significance of four MRD markers in MRD-based treatment strategy for childhood acute lymphoblastic leukemia
Akihisa Sawada, Naoki Sakata, Tomoko Kishimoto, Banryoku Higuchi, Maho Koyama, Osamu Kondo, Emiko Sato, Takayuki Okamura, Masahiro Yasui, Masami Inoue, Akira Yoshioka, Keisei Kawa
20091101
2009 Dec 1
Leuk Res
Significance of four MRD markers in MRD-based treatment strategy for childhood acute lymphoblastic leukemia
Leuk Res. 2009 Dec;33(12):1710-1713, Akihisa Sawada, Naoki Sakata, Tomoko Kishimoto, Banryoku Higuchi, Maho Koyama, Osamu Kondo, Emiko Sato, Takayuki Okamura, Masahiro Yasui, Masami Inoue, Akira Yoshioka, Keisei Kawa
Newly diagnosed children with ALL (n=32) were treated on a protocol incorporating minimal residual disease (MRD)-based treatment decisions. MRD was monitored at 4 time points by semi-quantitative PCR detection of antigen receptor gene rearrangement, flow cytometry, quantitative RT-PCR detection of chimeric gene transcripts and overexpressed WT1 mRNA. Four patients positive for MRD at week 5 were treated with an intensified regimen. Median follow-up was 5.0 years (range 3.8–6.6 years) with a 4-year...
Editors' Choice
Long-Term Posttransplant Bortezomib Boosts Outcome in Myeloma With del(17p13)
